Medicines optimisation

A clinical practice guideline on medicines optimisation is being developed by the National Institute for Health and Care Excellence for use in the NHS in England, Wales and Northern Ireland. The Royal Pharmaceutical Society (RPS) is registered as a stakeholder to comment on the provisional recommendations. Members are invited to submit their views to inform the RPS’s response (email

Last updated
The Pharmaceutical Journal, PJ, 25 October 2014, Vol 293, No 7833;293(7833):DOI:10.1211/PJ.2014.20066827

You may also be interested in